Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2024-09-26 Earnings Release
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
Earnings Release Classification · 100% confidence The document explicitly states it reports the consolidated half-year financial results and provides updates on key milestones achieved during H1 2024. It contains detailed financial figures for 'June 30, 2024' compared to previous periods, including operating results and cash positions. This structure and content align perfectly with a comprehensive report covering a period shorter than a year, which corresponds to the Interim / Quarterly Report definition (IR). It is not just an 'Earnings Release' (ER) as it contains extensive operational and clinical updates alongside the financials, and it is not a 10-K as it covers only half a year. H1 2024
2024-09-26 English
OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le point sur ses avancées
Earnings Release Classification · 99% confidence The document is titled "OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le point sur ses avancées" (OSE Immunotherapeutics announces remarkable 2024 half-year results and provides an update on its progress). It explicitly details financial results for the first half of 2024 (revenus du premier semestre 2024), clinical pipeline updates, and management commentary. The date of the announcement is September 26, 2024, reporting on the period ending June 30, 2024. This structure and content perfectly match the definition of an Interim / Quarterly Report (IR), which provides comprehensive financial information for a period shorter than a year. It is not merely an Earnings Release (ER) as it contains detailed financial figures and extensive clinical updates, nor is it a full Annual Report (10-K). H1 2024
2024-09-26 French
RAPPORT FINANCIER SEMESTRIEL
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2024' (Half-Year Financial Report as of June 30, 2024) for OSE Immunotherapeutics. It contains a comprehensive table of contents including consolidated financial statements (balance sheet, income statement, cash flow statement), notes to the financial statements, and a management report (Rapport semestriel d'activité). It also includes an attestation from the CEO. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2024
2024-09-26 French
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
Regulatory Filings Classification · 100% confidence The document is a press release from OSE Immunotherapeutics announcing the global launch of a Phase 3 clinical trial ('Artemia') for their cancer vaccine, Tedopi®. It details the trial's design, endpoints, and significance for regulatory registration. It also mentions presentations at upcoming medical conferences and provides an overview of the company's pipeline and platforms. This content is characteristic of an announcement intended to inform investors and the public about significant operational and clinical progress, rather than a formal regulatory filing like a 10-K, a detailed financial report (IR), or a proxy statement. Since it is a press release announcing clinical trial progress and pipeline updates, it best fits the 'Regulatory Filings' (RNS) category as a general corporate announcement, although it is highly specific. It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (10-K, IR). Given the nature of the announcement (clinical trial launch and pipeline update), RNS is the most appropriate general category for non-standard, material corporate news.
2024-09-10 English
OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à petit
Regulatory Filings Classification · 95% confidence The document is a press release from OSE Immunotherapeutics, dated September 10, 2024, announcing the international launch of its Phase 3 clinical trial ('Artemia') for the therapeutic vaccine Tedopi® in non-small cell lung cancer (NSCLC). It details the trial design, patient population, and mentions presentations of 'Trial in Progress' posters at major medical conferences (WCLC and ESMO). This content is a corporate update regarding clinical development progress and future regulatory steps (aiming for registration). It is not a formal regulatory filing like a 10-K, a formal earnings release (ER), a full interim report (IR), or a proxy statement (DEF 14A). Since it is a significant corporate announcement detailing operational and clinical milestones, it fits best under the general category of a Regulatory Filing (RNS) as a broad announcement, or potentially a Capital/Financing Update (CAP) if it were tied to fundraising, but here it is primarily an operational update. Given the options, and since it is a formal announcement of a major clinical step that supports future registration, it is classified as a general Regulatory Filing (RNS), as it doesn't fit the more specific operational/financial categories like ER, IR, or CAP. It is not a Report Publication Announcement (RPA) because it is the primary news release, not just an announcement that a report is available.
2024-09-10 French
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital" (Information relating to the total number of voting rights and shares comprising the capital). It explicitly states it is being issued in application of the French Commercial Code (Article L. 233-8 II) and AMF General Regulation (Article 223-16). It provides a table detailing the total number of shares and voting rights as of August 31, 2024. This type of mandatory periodic disclosure regarding the capital structure and voting rights is a specific regulatory filing requirement in France, often related to major shareholding notifications or general capital updates, but the core content is the official count of shares/votes. This aligns best with the category for Major Shareholding Notification (MRQ) or a general regulatory filing (RNS). Given the specific nature of reporting the total number of voting rights as required by securities law, MRQ is a strong candidate, as these reports often trigger when share capital changes or for periodic updates that affect major holdings calculations. However, since the definition for MRQ is 'Notification of changes in significant share ownership levels (crossing thresholds)', and this document reports the total capital count which is the basis for determining significant ownership, it fits the spirit of capital structure reporting. If a more specific category for 'Total Voting Rights' existed, it would be used. In the absence of such a specific code, and noting it is a mandatory regulatory disclosure about capital structure, it is closest to MRQ or RNS. Since it is a direct, mandatory disclosure about the capital base, and not just an announcement of a report, I will classify it as MRQ as it directly relates to the calculation basis for major shareholdings, or RNS if MRQ is too narrow. Given the options, MRQ covers notifications related to share capital structure changes that impact ownership reporting. Let's re-evaluate against the provided definitions. It is not an ER, IR, 10-K, or CT. It is a mandatory regulatory disclosure about the capital base. MRQ is for 'changes in significant share ownership levels'. This document reports the total capital, which is the denominator for those levels. Since it is a formal, required disclosure about the capital base, and not a general announcement (RPA/RNS), MRQ is the most contextually relevant fit among the specific options related to ownership/capital structure, even if it's a periodic total rather than a specific change notification. If it were purely a miscellaneous regulatory announcement, RNS would apply. I lean towards MRQ due to the explicit focus on voting rights and share count.
2024-09-03 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.